Literature DB >> 3242584

Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.

J G Kelly1, N B Deaney, J Lavan, J Noel.   

Abstract

1. Norfloxacin was administered as two daily 400 mg oral doses to eight elderly patients requiring treatment for urinary tract infections. Blood specimens were obtained for pharmacokinetic profiles following the first and fifteenth doses. Further specimens were obtained before each morning's dose of norfloxacin. Specimens of urine were obtained to ascertain if adequate antimicrobial concentrations were reached in these patients with diminished renal function. 2. Norfloxacin half-life was consistent with that expected in mild renal impairment and was not different between the first and fifteenth doses. Based on ratios of AUC values, accumulation is probably related to renal function, being greatest for creatinine clearance values below 30 ml min-1. 3. On the great majority of occasions, the urinary concentrations of norfloxacin exceeded 20 micrograms ml-1. On days 2-7, the mean percentage 12 h renal elimination of norfloxacin was 18.6 +/- 1.47 (mean of 82 separate observations). Norfloxacin 400 mg twice daily was well tolerated in this group of elderly patients and produced adequate antimicrobial concentrations in urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3242584      PMCID: PMC1386596          DOI: 10.1111/j.1365-2125.1988.tb05320.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Norfloxacin in acute urinary tract infections.

Authors:  N B Deaney; R Vogel; M J Vandenburg; W J Currie
Journal:  Practitioner       Date:  1984-01

2.  Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.

Authors:  P J Hughes; D B Webb; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

3.  Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

Authors:  M Eandi; I Viano; F Di Nola; L Leone; E Genazzani
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.

Authors:  J G Guerra; E Falconi; J C Palomino; L Benavente; E Antunez de Mayolo
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

5.  In vitro antibacterial activity of norfloxacin (MK-0366).

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

  6 in total
  1 in total

Review 1.  Quinolone disposition in the elderly. Practical implications.

Authors:  I Nilsson-Ehle; B Ljungberg
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.